Karuna Therapeutics, Inc. financial data

Symbol
KRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
99 High Street, 26 Th Floor, Boston, Massachusetts
Fiscal year end
December 31
Latest financial report
Q4 2023 - Feb 22, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.12K % +9.36%
Debt-to-equity 4.11 % -0.24%
Return On Equity -31.6 % +9.32%
Return On Assets -30.4 % +9.28%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38.2M shares +2.02%
Common Stock, Shares, Outstanding 38.1M shares +10.5%
Entity Public Float 5.87B USD +101%
Common Stock, Value, Issued 4K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 37M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 37M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 364M USD +62.4%
General and Administrative Expense 131M USD +72.7%
Operating Income (Loss) -495M USD -70.8%
Nonoperating Income (Expense) 61.8M USD +319%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -433M USD -57.5%
Income Tax Expense (Benefit) 670K USD -52.8%
Net Income (Loss) Attributable to Parent -434M USD -56.9%
Earnings Per Share, Basic -11.7 USD/shares -34.2%
Earnings Per Share, Diluted -11.7 USD/shares -34.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 186M USD -25.2%
Other Assets, Current 12.5M USD +701%
Assets, Current 1.32B USD +13.9%
Property, Plant and Equipment, Net 5.42M USD +69.4%
Operating Lease, Right-of-Use Asset 15.1M USD +223%
Other Assets, Noncurrent 382K USD -11%
Assets 1.34B USD +14.9%
Accounts Payable, Current 6.78M USD +185%
Employee-related Liabilities, Current 15.1M USD +26.7%
Accrued Liabilities, Current 41.6M USD +42.1%
Liabilities, Current 68.1M USD +101%
Operating Lease, Liability, Noncurrent 13.8M USD +355%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 82M USD +121%
Retained Earnings (Accumulated Deficit) -998M USD -76.9%
Stockholders' Equity Attributable to Parent 1.25B USD +11.4%
Liabilities and Equity 1.34B USD +14.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -386M USD -69.2%
Net Cash Provided by (Used in) Financing Activities 483M USD -43.5%
Net Cash Provided by (Used in) Investing Activities -160M USD +72.7%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 38.1M shares +10.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62.8M USD -252%
Deferred Tax Assets, Valuation Allowance 373M USD +65.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 377M USD +66%
Operating Lease, Liability 16.7M USD +213%
Depreciation 1.7M USD +54.5%
Payments to Acquire Property, Plant, and Equipment 2.92M USD +219%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -430M USD -54.1%
Lessee, Operating Lease, Liability, to be Paid 44.3M USD +673%
Property, Plant and Equipment, Gross 8.53M USD +74.8%
Operating Lease, Liability, Current 2.84M USD +24.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.82M USD +202%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.04M USD +20.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +85.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 18.5M USD +4393%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.59M USD +121%
Deferred Tax Assets, Operating Loss Carryforwards 150M USD +41.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.7M USD
Operating Lease, Payments 2.98M USD +16.8%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.7M USD +53%
Share-based Payment Arrangement, Expense 74.6M USD +57.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%